University of Arkansas
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
Healthy
Dexrazoxane
PHASE1
This is a study on volunteers to determine effective dose of dexrazoxane in degrading Topoisomerase 2 b in human blood samples. Each participant will receive one dose of dexrazoxane. Blood samples will be collected to determine the time course and degradation of Topoisomerase 2b and Topoisomerase 2a
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 25 participants |
| Masking : | NONE |
| Primary Purpose : | PREVENTION |
| Official Title : | Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane in Patients With Breast Cancer |
| Actual Study Start Date : | 2021-09-14 |
| Estimated Primary Completion Date : | 2025-10-31 |
| Estimated Study Completion Date : | 2026-10-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 65 Years |
| Sexes Eligible for Study: | FEMALE |
| Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Arkansas for Medical Sciences
Little Rock, Arkansa, United States, 72205